Boomerang Ventures Invests $250K Pre-Seed in EarSmartAI to Tackle $5B Pediatric Ear Infection Market
What's the deal? Boomerang Ventures has made a $250,000 pre-seed investment in EarSmartAI, an Indianapolis-based startup building an AI-powered platform to help parents diagnose pediatric ear infections from home. The company also named veteran MedTech entrepreneur Mark Terrill as chief executive officer and co-founder.
EarSmartAI's platform combines a smart otoscope, proprietary AI software, and a mobile app. Parents enter symptoms, capture an eardrum video with the device, and receive an AI-driven likelihood assessment to guide next steps in care. The company aims to reduce unnecessary medical visits, enable earlier intervention, and improve access to pediatric care.
Ear infections are the leading cause of pediatric office visits and antibiotic prescriptions in the US, with over 15 million annual cases and $5 billion in healthcare costs. With a projected pediatrician shortage of over 25,000 by 2030, scalable diagnostic solutions are urgently needed. EarSmartAI operates at the intersection of MedTech, artificial intelligence, and consumer telehealth.
The platform is built on more than 10 years of scientific research and was developed in collaboration with pediatric experts from the University of Pittsburgh, including renowned acute otitis media thought leaders Dr. Alejandro Hoberman and Dr. Nader Shaikh. The company's proprietary AI algorithms were trained using more than 1,500 annotated tympanic membrane videos and supported by clinically validated research published in JAMA in 2024.
Mark Terrill brings 20+ years of leadership, founding and scaling medical device companies, with multiple exits and an IPO. As CEO at Arc Medical, he led the company from startup to revenue and its acquisition. At Caliridia Medical, Terrill grew revenue from about $5 million to over $61 million as CEO, leading to acquisition.
"Parents today are dealing with tremendous stress when a child develops symptoms late at night, and immediate access to pediatric care is limited. EarSmartAI was designed to reduce that disruption by delivering a fast, convenient, and more accurate way to assess ear infections from home." — Mark Terrill, CEO and Co-Founder
EarSmartAI recently initiated its FDA human study and plans to pursue a De Novo FDA submission. Over the next 24 months, the company plans to advance FDA regulatory milestones, expand commercialization readiness, strengthen telehealth and distribution partnerships, and continue building scalable infrastructure for broader pediatric connected care applications.
EarSmartAI plans to generate revenue through connected device sales, software subscription services, and telehealth-related partnerships.
Source: AccessNewsWire
